# BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
Canonical URL: https://biopharmsignal.com/news/BRTX/biorestorative-expands-global-protection-for-thermostem-a-potentially-longer-las-7f787bd2
Ticker: BRTX
Company: BioRestorative
Source: BioRestorative
Published: 2026-02-24 13:30 EST
## Summary

GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular...

## Article Body
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks.

BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages.

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.”

The newly allowed patent application provides the broadest protection obtained for BioRestorative’s allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem ® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.

With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.

“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem ® .”

About BioRestorative Therapies, Inc.

BioRestorative ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC ™ ): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem ® ): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT: Stephen Kilmer Investor Relations Direct: (646) 274-3580 Email: skilmer@biorestorative.com
## Recent Company News
- 2026-06-25 12:15 EST — [BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-announces-completion-of-brtx-100-phase-2-manufacturing--27587c89) — Source: BioRestorative
- 2026-06-18 12:15 EST — [BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-e-e42cdec1) — Source: BioRestorative
- 2026-05-26 15:00 EST — [BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data](https://biopharmsignal.com/news/BRTX/biorestorative-completes-phase-2-dosing-of-brtx-100-advancing-lead-regenerative--8f9156be) — Source: BioRestorative
- 2026-05-13 15:00 EST — [BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-presents-new-preclinical-data-at-isct-2026-highlighting-9821fc30) — Source: BioRestorative
- 2026-05-07 16:00 EST — [BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-s-3dd6ee17) — Source: BioRestorative
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)